Who are RAL or EGV based ARV regimens with ABC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tenofovir Disoproxil, Lamuvidine and Dolutegravir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ral-or-egv-based-arv-regimens-with-abc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

RAL or EGV based ARV regimens with ABC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RAL or EGV based ARV regimens with ABC (RAL or EGV based ARV regimens with ABC) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV-1 integrase inhibitor. Area: Infectious Disease.

phase 2 HIV-1 integrase inhibitor HIV-1 integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

RAL or EGV based ARV regimens with ABC (RAL or EGV based ARV regimens with ABC) — ViiV Healthcare. Inhibits HIV-1 integrase

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RAL or EGV based ARV regimens with ABC TARGET	RAL or EGV based ARV regimens with ABC	ViiV Healthcare	phase 2	HIV-1 integrase inhibitor	HIV-1 integrase
Tenofovir Disoproxil, Lamuvidine and Dolutegravir	Tenofovir Disoproxil, Lamuvidine and Dolutegravir	Africa Health Research Institute	phase 3	NRTI/INST	HIV-1 reverse transcriptase, HIV-1 integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV-1 integrase inhibitor class)

ViiV Healthcare · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RAL or EGV based ARV regimens with ABC — Competitive Intelligence Brief. https://druglandscape.com/ci/ral-or-egv-based-arv-regimens-with-abc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab